使用口服活性神经肽Y Y1拮抗剂对Zucker肥胖大鼠体重增加和血浆皮质酮水平的阻断作用
Blockade of body weight gain and plasma corticosterone levels in Zucker fatty rats using an orally active neuropeptide Y Y1 antagonist.
作者信息
Ishihara Akane, Kanatani Akio, Okada Megumu, Hidaka Masayasu, Tanaka Takeshi, Mashiko Satoshi, Gomori Akira, Kanno Tetsuya, Hata Mikiko, Kanesaka Maki, Tominaga Yushin, Sato Naga-aki, Kobayashi Masahiko, Murai Takashi, Watanabe Keiko, Ishii Yasuyuki, Fukuroda Takahiro, Fukami Takehiro, Ihara Masaki
机构信息
Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba, Ibaraki 300-2611, Japan.
出版信息
Br J Pharmacol. 2002 Jun;136(3):341-6. doi: 10.1038/sj.bjp.0704696.
Abstract
- An experiment was conducted to examine whether a potent, orally active and highly selective neuropeptide Y Y1 receptor antagonist attenuates hyperphagia and obesity in genetically obese Zucker fatty rats. 2. Oral administration of the Y1 antagonist (30 and 100 mg x kg(-1), once daily for 2 weeks) significantly suppressed the daily food intake and body weight gain in Zucker fatty rats accompanied with a reduction of fat cell size and plasma corticosterone levels. 3. Despite the fact that food intake was gradually returned to near the control level, the body weight of the treated animals remained significantly less when compared to that of the controls for the duration of the treatment. 4. These results suggest that the Y1 receptor, at least in part, participate in pathophysiological feeding and/or fat accumulation observed in Zucker fatty rats. Y1 antagonists might be useful for the treatment of obesity.
摘要
- 进行了一项实验，以研究一种强效、口服活性且高度选择性的神经肽Y Y1受体拮抗剂是否能减轻遗传性肥胖的 Zucker 脂肪大鼠的食欲亢进和肥胖。2. 口服 Y1 拮抗剂（30 和 100 mg·kg⁻¹，每日一次，持续 2 周）可显著抑制 Zucker 脂肪大鼠的每日食物摄入量和体重增加，同时脂肪细胞大小和血浆皮质酮水平降低。3. 尽管食物摄入量逐渐恢复到接近对照水平，但在治疗期间，与对照组相比，治疗动物的体重仍显著较低。4. 这些结果表明，Y1 受体至少部分参与了 Zucker 脂肪大鼠中观察到的病理生理喂养和/或脂肪积累。Y1 拮抗剂可能对肥胖症的治疗有用。
相似文献
1
Blockade of body weight gain and plasma corticosterone levels in Zucker fatty rats using an orally active neuropeptide Y Y1 antagonist.使用口服活性神经肽Y Y1拮抗剂对Zucker肥胖大鼠体重增加和血浆皮质酮水平的阻断作用
Br J Pharmacol. 2002 Jun;136(3):341-6. doi: 10.1038/sj.bjp.0704696.
2
Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.新型选择性神经肽Y(1)受体拮抗剂BMS-193885的药理学特性及食欲抑制作用
Eur J Pharmacol. 2008 Aug 20;590(1-3):224-32. doi: 10.1016/j.ejphar.2008.06.032. Epub 2008 Jun 12.
3
Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis.神经肽Y1和Y5受体途径在能量稳态调节中的协同相互作用。
Eur J Pharmacol. 2009 Aug 1;615(1-3):113-7. doi: 10.1016/j.ejphar.2009.05.018. Epub 2009 May 29.
4
LY226936 administered orally and centrally to obese Zucker rats suppresses food intake and body weight gain.
Obes Res. 1994 Sep;2(5):458-68. doi: 10.1002/j.1550-8528.1994.tb00093.x.
5
Effect of phenylpiperidine opioid antagonists on food consumption and weight gain of the obese Zucker rat.
J Pharmacol Exp Ther. 1990 Apr;253(1):85-9.
6
The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.新型神经肽Y Y(1)受体拮抗剂J - 104870：一种具有口服生物利用度的强效食欲抑制剂。
Biochem Biophys Res Commun. 1999 Dec 9;266(1):88-91. doi: 10.1006/bbrc.1999.1750.
7
A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814.一种典型的Y1受体调节进食行为：强效选择性Y1拮抗剂J-115814的作用
Mol Pharmacol. 2001 Mar;59(3):501-5. doi: 10.1124/mol.59.3.501.
8
Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y.噻唑烷二酮类药物BRL 49653（罗格列酮）增加肥胖型 Zucker 大鼠的摄食量及瘦素和下丘脑神经肽Y可能参与其中
Br J Pharmacol. 1997 Dec;122(7):1405-10. doi: 10.1038/sj.bjp.0701535.
9
Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.FMS586[3-(5,6,7,8-四氢-9-异丙基-咔唑-3-基)-1-甲基-1-(2-吡啶-4-基-乙基)-脲盐酸盐]的药理学特性及摄食抑制特性，一种新型、选择性且口服活性的神经肽Y Y5受体拮抗剂。
J Pharmacol Exp Ther. 2006 May;317(2):562-70. doi: 10.1124/jpet.105.099705. Epub 2006 Jan 25.
10
Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats.在（fa/fa） Zucker大鼠中，中枢注射艾塞那肽-4可减轻体重，而不改变血浆瘦素水平。
Obes Res. 2000 Jul;8(4):317-23. doi: 10.1038/oby.2000.38.
引用本文的文献
1
New targets to treat obesity and the metabolic syndrome.治疗肥胖症和代谢综合征的新靶点。
Eur J Pharmacol. 2015 Sep 15;763(Pt A):64-74. doi: 10.1016/j.ejphar.2015.03.093. Epub 2015 May 19.
2
Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists.新型双环[3.1.0]己基哌嗪类作为非竞争性神经肽Y Y1拮抗剂的发现。
ACS Med Chem Lett. 2012 Jan 4;3(3):222-6. doi: 10.1021/ml200265m. eCollection 2012 Mar 8.
3
Review of the neuroanatomic landscape implicated in glucose sensing and regulation of nutrient signaling: immunophenotypic localization of diabetes gene Tcf7l2 in the developing murine brain.探讨神经解剖学在葡萄糖感应和营养信号调节中的作用：糖尿病基因 Tcf7l2 在发育中鼠脑的免疫表型定位。
J Chem Neuroanat. 2012 Oct;45(1-2):1-17. doi: 10.1016/j.jchemneu.2012.06.002. Epub 2012 Jul 13.
4
NPY receptors as potential targets for anti-obesity drug development.神经肽 Y 受体作为抗肥胖药物开发的潜在靶点。
Br J Pharmacol. 2011 Jul;163(6):1170-202. doi: 10.1111/j.1476-5381.2011.01363.x.
5
Delayed stress-induced differences in locomotor and depression-related behaviour in female neuropeptide-Y Y1 receptor knockout mice.延迟应激诱导的神经肽 Y Y1 受体敲除雌性小鼠运动和抑郁相关行为的差异。
J Psychopharmacol. 2010 Oct;24(10):1541-9. doi: 10.1177/0269881109104851. Epub 2009 Apr 7.
6
A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice.神经肽Y Y5拮抗剂可选择性改善饮食诱导肥胖小鼠的体重增加及相关指标。
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7154-8. doi: 10.1073/pnas.0510320103. Epub 2006 Apr 24.
本文引用的文献
1
Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism.向C57BL/6J雄性小鼠侧脑室长期注射神经肽Y会产生一种肥胖综合征，包括食欲亢进、高瘦素血症、胰岛素抵抗和性腺功能减退。
Mol Cell Endocrinol. 2001 Dec 20;185(1-2):195-204. doi: 10.1016/s0303-7207(01)00620-7.
2
A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814.一种典型的Y1受体调节进食行为：强效选择性Y1拮抗剂J-115814的作用
Mol Pharmacol. 2001 Mar;59(3):501-5. doi: 10.1124/mol.59.3.501.
3
L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.L-152,804：口服活性且具有选择性的神经肽Y Y5受体拮抗剂。
Biochem Biophys Res Commun. 2000 May 27;272(1):169-73. doi: 10.1006/bbrc.2000.2696.
4
Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice.Y1受体在神经肽Y介导的进食调节中的作用：野生型、Y1受体缺陷型和Y5受体缺陷型小鼠的比较
Endocrinology. 2000 Mar;141(3):1011-6. doi: 10.1210/endo.141.3.7387.
5
The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.新型神经肽Y Y(1)受体拮抗剂J - 104870：一种具有口服生物利用度的强效食欲抑制剂。
Biochem Biophys Res Commun. 1999 Dec 9;266(1):88-91. doi: 10.1006/bbrc.1999.1750.
6
NPY-induced feeding involves the action of a Y1-like receptor in rodents.神经肽Y诱导的进食涉及啮齿动物中一种类Y1受体的作用。
Regul Pept. 1998 Sep 25;75-76:409-15. doi: 10.1016/s0167-0115(98)00096-2.
7
Evidence of altered hypothalamic pro-opiomelanocortin/ neuropeptide Y mRNA expression in tubby mice.肥胖小鼠下丘脑阿黑皮素原/神经肽Y信使核糖核酸表达改变的证据。
Brain Res Mol Brain Res. 1998 Aug 31;59(2):273-9. doi: 10.1016/s0169-328x(98)00150-8.
8
A potent neuropeptide Y antagonist, 1229U91, suppressed spontaneous food intake in Zucker fatty rats.
Am J Physiol. 1998 May;274(5):R1500-4. doi: 10.1152/ajpregu.1998.274.5.R1500.
9
Y-receptor subtypes--how many more?Y受体亚型——还有多少？
Trends Neurosci. 1997 Jul;20(7):294-8. doi: 10.1016/s0166-2236(96)01057-0.
10
Regionally-selective down-regulation of NPY receptor subtypes in the obese Zucker rat. Relationship to the Y5 'feeding' receptor.肥胖 Zucker 大鼠中 NPY 受体亚型的区域选择性下调。与 Y5“进食”受体的关系。
Brain Res. 1997 May 30;758(1-2):17-25. doi: 10.1016/s0006-8993(97)00160-1.
Zotero 插件